ROCKLAND, Mass. and
NEW YORK, Jan. 6, 2020 /PRNewswire/ -- EMD Serono, the
biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today
announced the Phase III JAVELIN Bladder 100 study met its primary
endpoint of overall survival (OS) at the planned interim analysis.
In this study, patients with previously untreated locally advanced
or metastatic urothelial carcinoma (UC) whose disease did not
progress on induction chemotherapy and who were randomized to
receive first-line maintenance therapy with BAVENCIO®
(avelumab)* and best supportive care (BSC) lived significantly
longer than those who received BSC only. A statistically
significant improvement in OS was demonstrated in the BAVENCIO arm
in each of the co-primary populations: all randomized patients and
patients with PD-L1–positive tumors. The safety profile for
BAVENCIO in the trial was consistent with that in the JAVELIN
monotherapy clinical development program. The results of the study
will be submitted for presentation at an upcoming medical congress
and shared with the US Food and Drug Administration (FDA) and other
health authorities.
"BAVENCIO is the first immunotherapy to demonstrate in a
clinical trial a statistically significant improvement in overall
survival as a first-line treatment for patients with
advanced urothelial carcinoma," said Chris Boshoff, M.D., Ph.D., Chief Development
Officer, Oncology, Pfizer Global Product Development. "These
latest positive data from the JAVELIN clinical development program
add to the body of evidence for BAVENCIO in the treatment of
genitourinary cancers, and we look forward to discussing these
results with health authorities."
UC accounts for about 90% of all bladder cancer.1
When bladder cancer is metastatic, the five-year survival rate is
5%.2 Combination chemotherapy is currently the
first-line standard of care for patients with advanced disease, but
despite high initial response rates, durable and complete responses
following first-line chemotherapy are uncommon, and most patients
will ultimately experience disease progression within nine months
after initiation of treatment.3,4
"Our unique maintenance approach with BAVENCIO has significantly
prolonged survival for patients with locally advanced or metastatic
urothelial carcinoma in this trial," said Luciano Rossetti, Head of Global R&D for EMD
Serono. "We believe this approach could become part of routine
clinical practice, as these results are a major advance on the
existing standard of care."
In 2017, the FDA approved BAVENCIO for the treatment of patients
with locally advanced or metastatic urothelial carcinoma who have
disease progression during or following platinum-containing
chemotherapy, or who have disease progression within 12 months of
neoadjuvant or adjuvant treatment with platinum-containing
chemotherapy. This indication is approved under accelerated
approval based on tumor response and duration of response. JAVELIN
Bladder 100 is the confirmatory study for the conversion to full
approval.
*BAVENCIO is under clinical investigation for the first-line
maintenance treatment of advanced UC. There is no guarantee that
BAVENCIO will be approved for first-line maintenance treatment of
UC by any health authority worldwide.
About JAVELIN Bladder 100
JAVELIN Bladder 100 (NCT02603432) is a Phase III, multicenter,
multinational, randomized, open-label, parallel-arm study
investigating first-line maintenance treatment with BAVENCIO plus
BSC versus BSC alone in patients with locally advanced or
metastatic UC whose disease did not progress after completion of
first-line platinum-containing chemotherapy. A total of 700
patients whose disease had not progressed after induction
chemotherapy as per RECIST v1.1 were randomly assigned to receive
either BAVENCIO plus BSC or BSC alone. The primary endpoint is OS
in co-primary populations of all patients and patients with
PD-L1–positive tumors. Secondary endpoints include progression-free
survival, anti-tumor activity, safety, pharmacokinetics,
immunogenicity, predictive biomarkers and patient-reported outcomes
in the co-primary populations.
About Urothelial Carcinoma
Bladder cancer is the
tenth most common cancer worldwide.5 In 2018, there were
over half a million new cases of bladder cancer diagnosed, with
around 200,000 deaths from the disease globally.5 UC
accounts for about 90% of all bladder cancers.6 This
subtype becomes harder to treat as it advances, spreading through
the layers of the bladder wall.7 For patients with
metastatic bladder cancer, the five-year survival rate is
5%.2 Given the poor prognosis for patients with advanced
bladder cancer whose disease progresses after first-line
chemotherapy, there is an urgent need for additional treatment
options that improve overall survival.8
About the JAVELIN Clinical Development Program
The
clinical development program for BAVENCIO, known as JAVELIN,
involves more than 10,000 patients evaluated across more than 15
different tumor types. In addition to urothelial carcinoma, these
tumor types include head and neck cancer, Merkel cell carcinoma,
non-small cell lung cancer and renal cell carcinoma.
About BAVENCIO®
(avelumab)
BAVENCIO is a human anti-programmed death
ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical
models to engage both the adaptive and innate immune functions. By
blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has
been shown to release the suppression of the T cell-mediated
antitumor immune response in preclinical models.9-11 In
November 2014, Merck KGaA, Darmstadt,
Germany and Pfizer announced a
strategic alliance to co-develop and co-commercialize
BAVENCIO.
BAVENCIO Approved Indications
BAVENCIO®
(avelumab) in combination with axitinib is indicated in the US for
the first-line treatment of patients with advanced renal cell
carcinoma (RCC).
In the US, the FDA granted accelerated approval for BAVENCIO for
the treatment of (i) adults and pediatric patients 12 years and
older with metastatic Merkel cell carcinoma (mMCC) and (ii)
patients with locally advanced or metastatic urothelial carcinoma
(mUC) who have disease progression during or following
platinum-containing chemotherapy, or have disease progression
within 12 months of neoadjuvant or adjuvant treatment with
platinum-containing chemotherapy. These indications are approved
under accelerated approval based on tumor response rate and
duration of response. Continued approval for these indications may
be contingent upon verification and description of clinical benefit
in confirmatory trials.
Avelumab is currently approved for patients with MCC in 50
countries globally, with the majority of these approvals in a broad
indication that is not limited to a specific line of treatment.
BAVENCIO Important Safety Information from the US
FDA-Approved Label
BAVENCIO can cause immune-mediated
pneumonitis, including fatal cases. Monitor patients for signs
and symptoms of pneumonitis, and evaluate suspected cases with
radiographic imaging. Administer corticosteroids for Grade 2 or
greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and
permanently discontinue for severe (Grade 3), life-threatening
(Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis
occurred in 1.2% of patients, including one (0.1%) patient with
Grade 5, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.
BAVENCIO can cause hepatotoxicity and immune-mediated
hepatitis, including fatal cases. Monitor patients for abnormal
liver tests prior to and periodically during treatment. Administer
corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO
for moderate (Grade 2) immune-mediated hepatitis until resolution
and permanently discontinue for severe (Grade 3) or
life-threatening (Grade 4) immune-mediated hepatitis.
Immune-mediated hepatitis occurred with BAVENCIO as a single agent
in 0.9% of patients, including two (0.1%) patients with Grade 5,
and 11 (0.6%) with Grade 3.
BAVENCIO in combination with
axitinib can cause hepatotoxicity with higher than
expected frequencies of Grade 3 and 4 alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) elevation. Consider more
frequent monitoring of liver enzymes as compared to when the drugs
are used as monotherapy. Withhold BAVENCIO and axitinib for
moderate (Grade 2) hepatotoxicity and permanently discontinue the
combination for severe or life-threatening (Grade 3 or 4)
hepatotoxicity. Administer corticosteroids as needed. In patients
treated with BAVENCIO in combination with axitinib, Grades 3
and 4 increased ALT and AST occurred in 9% and 7% of patients,
respectively, and immune-mediated hepatitis occurred in 7% of
patients, including 4.9% with Grade 3 or 4.
BAVENCIO can cause immune-mediated colitis. Monitor
patients for signs and symptoms of colitis. Administer
corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO
until resolution for moderate or severe (Grade 2 or 3) colitis
until resolution. Permanently discontinue for life-threatening
(Grade 4) or recurrent (Grade 3) colitis upon reinitiation of
BAVENCIO. Immune-mediated colitis occurred in 1.5% of patients,
including seven (0.4%) with Grade 3.
BAVENCIO can cause immune-mediated endocrinopathies,
including adrenal insufficiency, thyroid disorders, and type 1
diabetes mellitus.
Monitor patients for signs and
symptoms of adrenal insufficiency during and after
treatment, and administer corticosteroids as appropriate. Withhold
BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) adrenal
insufficiency. Adrenal insufficiency was reported in 0.5% of
patients, including one (0.1%) with Grade 3.
Thyroid disorders can occur
at any time during treatment. Monitor patients for changes in
thyroid function at the start of treatment, periodically during
treatment, and as indicated based on clinical evaluation. Manage
hypothyroidism with hormone replacement therapy and hyperthyroidism
with medical management. Withhold BAVENCIO for severe (Grade 3) or
life-threatening (Grade 4) thyroid disorders. Thyroid disorders,
including hypothyroidism, hyperthyroidism, and thyroiditis, were
reported in 6% of patients, including three (0.2%) with Grade
3.
Type 1 diabetes mellitus
including diabetic ketoacidosis: Monitor patients for hyperglycemia
or other signs and symptoms of diabetes. Withhold BAVENCIO and
administer antihyperglycemics or insulin in patients with severe or
life-threatening (Grade ≥3) hyperglycemia, and resume treatment
when metabolic control is achieved. Type 1 diabetes mellitus
without an alternative etiology occurred in 0.1% of patients,
including two cases of Grade 3 hyperglycemia.
BAVENCIO can cause immune-mediated nephritis and renal
dysfunction. Monitor patients for elevated serum creatinine
prior to and periodically during treatment. Administer
corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO
for moderate (Grade 2) or severe (Grade 3) nephritis until
resolution to Grade 1 or lower. Permanently discontinue BAVENCIO
for life-threatening (Grade 4) nephritis. Immune-mediated nephritis
occurred in 0.1% of patients.
BAVENCIO can result in other severe and fatal immune-mediated
adverse reactions involving any organ system during treatment
or after treatment discontinuation. For suspected immune-mediated
adverse reactions, evaluate to confirm or rule out an
immune-mediated adverse reaction and to exclude other causes.
Depending on the severity of the adverse reaction, withhold or
permanently discontinue BAVENCIO, administer high-dose
corticosteroids, and initiate hormone replacement therapy, if
appropriate. Resume BAVENCIO when the immune-mediated adverse
reaction remains at Grade 1 or lower following a corticosteroid
taper. Permanently discontinue BAVENCIO for any severe (Grade 3)
immune-mediated adverse reaction that recurs and for any
life-threatening (Grade 4) immune-mediated adverse reaction. The
following clinically significant immune-mediated adverse reactions
occurred in less than 1% of 1738 patients treated with BAVENCIO as
a single agent or in 489 patients who received BAVENCIO in
combination with axitinib: myocarditis including fatal cases,
pancreatitis including fatal cases, myositis, psoriasis, arthritis,
exfoliative dermatitis, erythema multiforme, pemphigoid,
hypopituitarism, uveitis, Guillain-Barré syndrome, and systemic
inflammatory response.
BAVENCIO can cause severe or life-threatening
infusion-related reactions. Premedicate patients with an
antihistamine and acetaminophen prior to the first 4 infusions and
for subsequent infusions based upon clinical judgment and
presence/severity of prior infusion reactions. Monitor patients for
signs and symptoms of infusion-related reactions, including
pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back
pain, abdominal pain, and urticaria. Interrupt or slow the rate of
infusion for mild (Grade 1) or moderate (Grade 2) infusion-related
reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or
life-threatening (Grade 4) infusion-related reactions.
Infusion-related reactions occurred in 25% of patients, including
three (0.2%) patients with Grade 4 and nine (0.5%) with Grade
3.
BAVENCIO in combination with axitinib can cause major
adverse cardiovascular events (MACE) including severe and fatal
events. Consider baseline and periodic evaluations of left
ventricular ejection fraction. Monitor for signs and symptoms of
cardiovascular events. Optimize management of cardiovascular risk
factors, such as hypertension, diabetes, or dyslipidemia.
Discontinue BAVENCIO and axitinib for Grade 3-4 cardiovascular
events. MACE occurred in 7% of patients with advanced RCC
treated with BAVENCIO in combination with axitinib compared to 3.4%
treated with sunitinib. These events included death due to cardiac
events (1.4%), Grade 3-4 myocardial infarction (2.8%), and Grade
3-4 congestive heart failure (1.8%).
BAVENCIO can cause fetal harm when administered to a
pregnant woman. Advise patients of the potential risk to a fetus
including the risk of fetal death. Advise females of childbearing
potential to use effective contraception during treatment with
BAVENCIO and for at least 1 month after the last dose of BAVENCIO.
It is not known whether BAVENCIO is excreted in human milk. Advise
a lactating woman not to breastfeed during treatment and for
at least 1 month after the last dose of BAVENCIO due to the
potential for serious adverse reactions in breastfed infants.
The most common adverse reactions (all grades, ≥ 20%) in
patients with metastatic Merkel cell carcinoma (MCC) were fatigue
(50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%),
infusion-related reaction (22%), rash (22%), decreased appetite
(20%), and peripheral edema (20%).
Selected treatment-emergent laboratory abnormalities (all
grades, ≥ 20%) in patients with metastatic MCC were lymphopenia
(49%), anemia (35%), increased aspartate aminotransferase (34%),
thrombocytopenia (27%), and increased alanine aminotransferase
(20%).
The most common adverse reactions (all grades, ≥ 20%) in
patients with locally advanced or metastatic urothelial carcinoma
(UC) were fatigue (41%), infusion-related reaction (30%),
musculoskeletal pain (25%), nausea (24%), decreased
appetite/hypophagia (21%), and urinary tract infection (21%).
Selected laboratory abnormalities (Grades 3-4, ≥ 3%) in patients
with locally advanced or metastatic UC were hyponatremia (16%),
increased gamma-glutamyltransferase (12%), lymphopenia (11%),
hyperglycemia (9%), increased alkaline phosphatase (7%), anemia
(6%), increased lipase (6%), hyperkalemia (3%), and increased
aspartate aminotransferase (3%).
Fatal adverse reactions occurred in 1.8% of patients with
advanced renal cell carcinoma (RCC) receiving BAVENCIO in
combination with axitinib. These included sudden cardiac death
(1.2%), stroke (0.2%), myocarditis (0.2%), and necrotizing
pancreatitis (0.2%).
The most common adverse reactions (all grades, ≥20%) in patients
with advanced RCC receiving BAVENCIO in combination with axitinib
(vs sunitinib) were diarrhea (62% vs 48%), fatigue (53% vs 54%),
hypertension (50% vs 36%), musculoskeletal pain (40% vs 33%),
nausea (34% vs 39%), mucositis (34% vs 35%), palmar-plantar
erythrodysesthesia (33% vs 34%), dysphonia (31% vs 3.2%), decreased
appetite (26% vs 29%), hypothyroidism (25% vs 14%), rash (25% vs
16%), hepatotoxicity (24% vs 18%), cough (23% vs 19%), dyspnea (23%
vs 16%), abdominal pain (22% vs 19%), and headache (21% vs
16%).
Selected laboratory abnormalities (all grades, ≥20%) worsening
from baseline in patients with advanced RCC receiving BAVENCIO in
combination with axitinib (vs sunitinib) were blood triglycerides
increased (71% vs 48%), blood creatinine increased (62% vs 68%),
blood cholesterol increased (57% vs 22%), alanine aminotransferase
increased (ALT) (50% vs 46%), aspartate aminotransferase increased
(AST) (47% vs 57%), blood sodium decreased (38% vs 37%), lipase
increased (37% vs 25%), blood potassium increased (35% vs 28%),
platelet count decreased (27% vs 80%), blood bilirubin increased
(21% vs 23%), and hemoglobin decreased (21% vs 65%).
Please see full US Prescribing Information and Medication Guide
available at http://www.BAVENCIO.com.
About Merck KGaA, Darmstadt, Germany-Pfizer
Alliance
Immuno-oncology is a top priority for Merck KGaA,
Darmstadt, Germany and Pfizer. The
global strategic alliance between Merck KGaA, Darmstadt,
Germany and Pfizer enables the
companies to benefit from each other's strengths and capabilities
and further explore the therapeutic potential of BAVENCIO, an
anti-PD-L1 antibody initially discovered and developed by Merck
KGaA, Darmstadt, Germany. The
immuno-oncology alliance is jointly developing and commercializing
BAVENCIO. The alliance is focused on developing high-priority
international clinical programs to investigate BAVENCIO as a
monotherapy as well as combination regimens, and is striving to
find new ways to treat cancer.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by
e-mail at the same time they become available on the EMD Group
Website. In case you are a resident of the USA or Canada
please go to www.emdgroup.com/subscribe to register again for
your online subscription of this service as our newly introduced
geo-targeting requires new links in the email. You may later change
your selection or discontinue this service.
About EMD Serono, Inc.
EMD Serono - the
biopharmaceutical business of Merck KGaA, Darmstadt, Germany,
in the U.S. and Canada - is engaged in the discovery,
research and development of medicines for patients with difficult
to treat diseases. The business is committed to transforming lives
by developing and delivering meaningful solutions that help address
the therapeutic and support needs of individual patients. Building
on a proven legacy and deep expertise in neurology, fertility and
endocrinology, EMD Serono is developing potential new oncology and
immuno-oncology medicines while continuing to explore potential
therapeutic options for diseases such as psoriasis, lupus and MS.
Today, the business has approximately 1,500 employees around the
country with commercial, clinical and research operations based in
the company's home state
of Massachusetts. www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt,
Germany, a leading science and
technology company, operates across healthcare, life science and
performance materials. Around 56,000 employees work to make a
positive difference to millions of people's lives every day by
creating more joyful and sustainable ways to live. From advancing
gene editing technologies and discovering unique ways to treat the
most challenging diseases to enabling the intelligence of devices –
the company is everywhere. In 2018, Merck KGaA, Darmstadt,
Germany, generated sales of € 14.8
billion in 66 countries.
The company holds the global rights to the name and trademark
"Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck
KGaA, Darmstadt, Germany operate
as EMD Serono in healthcare, MilliporeSigma in life science, and
EMD Performance Materials. Since its founding 1668, scientific
exploration and responsible entrepreneurship have been key to the
company's technological and scientific advances. To this day, the
founding family remains the majority owner of the publicly listed
company.
Pfizer Inc.: Breakthroughs that change patients'
lives
At Pfizer, we apply science and our global resources
to bring therapies to people that extend and significantly improve
their lives. We strive to set the standard for quality, safety and
value in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.pfizer.com. In addition, to
learn more, please visit us on www.pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer_News, LinkedIn,
YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice
The information contained in
this release is as of January 6,
2020. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking information about BAVENCIO
(avelumab), including a potential indication for first-line
maintenance therapy and a second-line treatment indication approved
in the U.S. for BAVENCIO for the treatment of patients with locally
advanced or metastatic urothelial carcinoma, the alliance between
Merck KGaA, Darmstadt, Germany, and Pfizer involving BAVENCIO and
clinical development plans, including their potential benefits,
that involves substantial risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statements. Risks and uncertainties include, among other
things, uncertainties regarding the commercial success of BAVENCIO;
the uncertainties inherent in research and development, including
the ability to meet anticipated clinical endpoints, commencement
and/or completion dates for our clinical trials, regulatory
submission dates, regulatory approval dates and/or launch dates, as
well as the possibility of unfavorable new clinical data and
further analyses of existing clinical data; risks associated with
interim data; the risk that clinical trial data are subject to
differing interpretations and assessments by regulatory
authorities; whether regulatory authorities will be satisfied with
the design of and results from our clinical studies; whether and
when any drug applications may be filed for BAVENCIO for
first-line maintenance therapy for locally advanced or metastatic
urothelial carcinoma in any jurisdictions, the second-line
treatment for locally advanced or metastatic urothelial carcinoma
outside the U.S. or in any jurisdictions for any other potential
indications for BAVENCIO or combination therapies; whether and when
regulatory authorities in any jurisdictions where any applications
are pending or may be submitted for BAVENCIO or combination
therapies, including BAVENCIO for locally advanced or metastatic
urothelial carcinoma may approve any such applications, which will
depend on myriad factors, including making a determination as to
whether the product's benefits outweigh its known risks and
determination of the product's efficacy, and, if approved, whether
they will be commercially successful; decisions by regulatory
authorities impacting labeling, manufacturing processes, safety
and/or other matters that could affect the availability or
commercial potential of BAVENCIO, including BAVENCIO for locally
advanced or metastatic urothelial carcinoma; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, and in its
subsequent reports on Form 10-Q, including in the sections thereof
captioned "Risk Factors" and "Forward-Looking Information and
Factors That May Affect Future Results", as well as in its
subsequent reports on Form 8-K, all of which are filed with the
U.S. Securities and Exchange Commission and available at
www.sec.gov and www.pfizer.com.
References
- Cancer.net. Bladder Cancer: Introduction.
https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed
January 2020.
- SEER. Cancer Stat Facts: Bladder Cancer.
https://seer.cancer.gov/statfacts/html/urinb.html. Accessed
January 2020.
- Bukhari N, et al. Update on the Treatment of Metastatic
Urothelial Carcinoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011065/. Accessed
January 2020.
- Von der Maase H, et al. Comparing Gemcitabine Plus Cisplatin,
With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in
patients With Bladder Cancer. Journal of Clinical Oncology.
2005;23(21):4602-4608.
- Bray F, et al. Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA: A Cancer Journal. 2018;68(6):394-424.
- Cancer.net. Bladder Cancer: Introduction.
https://www.cancer.net/cancer-types/bladder-cancer/introduction.
Accessed January 2020.
- American Cancer Society. What is Bladder Cancer?
https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html.
Accessed January 2020.
- Dietrich B, Srinivas S. Urothelial carcinoma: the evolving
landscape of immunotherapy for patients with advanced disease.
Res Rep Urol. 2018;10:7-16.
- Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the
landscape of cancer immunotherapy. Cancer Control.
2014;21(3):231-237.
- Dahan R, Sega E, Engelhardt J, et al. FcγRs modulate the
anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis.
Cancer Cell. 2015;28(3):285-295.
- Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent
cellular cytotoxicity activity of a novel anti-PD-L1 antibody
avelumab (MSB0010718C) on human tumor cells. Cancer Immunol
Res. 2015;3(10):1148-1157.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bavencio-significantly-improved-overall-survival-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-300981078.html
SOURCE EMD Serono